Vigani Barbara, Rossi Silvia, Sandri Giuseppina, Bonferoni Maria Cristina, Caramella Carla M
Department of Drug Sciences, University of Pavia, Pavia, Italy.
Front Drug Saf Regul. 2023 Aug 4;3:1227763. doi: 10.3389/fdsfr.2023.1227763. eCollection 2023.
The paper is intended to deal with the regulatory status of the family of substance-based medical devices (SB-MD) which contain mucoadhesive polymers. Mucoadhesive formulations are mainly intended for oral/buccal, gastro-esophageal, nasal, or vaginal administration routes. They contain one or more substances/polymers of either natural, synthetic or semi-synthetic origin endowed with mucoadhesive properties. These are complex substances whose chemical-physical properties are in general well characterized. Hydration and water retaining properties, gel formation, lubricating properties are example of functional characteristics that may be involved in mucosal interaction. However, there are still uncertainties as to the underlaying mechanisms. The idea is to provide support, to the understanding of the prevailing mechanisms of action of the family of SB-MD that exploit mucoadhesion phenomenon to exert the intended therapeutic action. A case study on Hyaluronic acid as a typical representative of mucoadhesive polymers, is presented. The correct understanding of the mechanism of action of the substances/polymers involved in SB-MD is pivotal to a smooth and successful submission to the involved regulatory bodies to a positive assessment and to the final approval.
本文旨在探讨含有粘膜粘附聚合物的基于物质的医疗器械(SB-MD)家族的监管状况。粘膜粘附制剂主要用于口服/颊部、胃食管、鼻腔或阴道给药途径。它们含有一种或多种天然、合成或半合成来源的具有粘膜粘附特性的物质/聚合物。这些是复杂的物质,其化学物理性质通常已得到很好的表征。水合和保水特性、凝胶形成、润滑特性是可能参与粘膜相互作用的功能特性的例子。然而,其潜在机制仍存在不确定性。目的是为理解SB-MD家族利用粘膜粘附现象发挥预期治疗作用的主要作用机制提供支持。本文以透明质酸作为粘膜粘附聚合物的典型代表进行了案例研究。正确理解SB-MD中所涉及的物质/聚合物的作用机制,对于顺利且成功地向相关监管机构提交申请以获得积极评估和最终批准至关重要。